508 Bibliografia [1] M. Grube, E. Holler, D. Weber, B. Holler, W. Herr, e D. Wolff, «Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study», Biol. Blood Marrow Transplant., vol. 22, n. 10, pagg. 1781–1791, ott. 2016, doi: 10.1016/j. bbmt.2016.06.020. [2] B. K. Hamilton, O. Goje, B. N. Savani, N. S. Majhail, e P. Stratton, «Clinical management of genital chronic GvHD», Bone Marrow Transplant., vol. 52, n. 6, pagg. 803–810, giu. 2017, doi: 10.1038/ bmt.2016.315. [3] S. M. Mueller et al., «Genital Chronic GVHD in Men after Hematopoietic Stem Cell Transplantation: A Single-Center Cross-Sectional Analysis of 155 Patients», Biol. Blood Marrow Transplant., vol. 19, n. 11, pagg. 1574–1580, nov. 2013, doi: 10.1016/j. bbmt.2013.07.010. [4] S. Spinelli et al., «Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation», Haematologica, vol. 88, n. 10, pagg. 1163–1168, ott. 2003. [5] A. M. N. Machado, N. Hamerschlak, M. Rodrigues, C. de A. Piccinato, S. Podgaec, e L. M. Q. Mauad, «Female genital tract chronic graft-versus-host disease: A narrative review», Hematol. Transfus. Cell Ther., vol. 41, n. 1, pagg. 69–75, gen. 2019, doi: 10.1016/j. htct.2018.06.005. [6] P. A. Carpenter et al., «National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report», Biol. Blood Marrow Transplant., vol. 21, n. 7, pagg. 1167–1187, lug. 2015, doi: 10.1016/j. bbmt.2015.03.024. [7] C. P. Chung, R. E. Sargent, N. T. Chung, J. V. Lacey, e M. T. Wakabayashi, «Graft-versus-Host Disease–Associated Vulvovaginal Symptoms after Bone Marrow Transplantation», Biol. Blood Marrow Transplant., vol. 22, n. 2, pagg. 378–379, feb. 2016, doi: 10.1016/j.bbmt.2015.09.021. [8] E. Smith Knutsson et al., «Genital Chronic Graft-versusHost Disease in Females: A Cross-Sectional Study», Biol. Blood Marrow Transplant., vol. 20, n. 6, pagg. 806–811, giu. 2014, doi: 10.1016/j.bbmt.2014.02.016. [9] L. B. Spiryda, M. R. Laufer, R. J. Soiffer, e J. A. Antin, «Graftversus-host disease of the vulva and/or vagina: diagnosis and treatment», Biol. Blood Marrow Transplant., vol. 9, n. 12, pagg. 760–765, dic. 2003, doi: 10.1016/j.bbmt.2003.08.001. [10] D. Zantomio, A. P. Grigg, L. MacGregor, Y. Panek-Hudson, J. Szer, e R. Ayton, «Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management», Bone Marrow Transplant., vol. 38, n. 8, pagg. 567–572, ott. 2006, doi: 10.1038/sj.bmt.1705487. Ringraziamenti Dott. Zallio Francesco e Dott.ssa Butera Sara, S.C.D.U. Ematologia e Centro Trapianti, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria. [11] D. Couriel et al., «Ancillary Therapy and Supportive Care of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report», Biol. Blood Marrow Transplant., vol. 12, n. 4, pagg. 375–396, apr. 2006, doi: 10.1016/j. bbmt.2006.02.003. [12] P. Stratton et al., «Vulvovaginal Chronic Graft-Versus-Host Disease With Allogeneic Hematopoietic Stem Cell Transplantation», Obstet. Gynecol., vol. 110, n. 5, pagg. 1041–1049, nov. 2007, doi: 10.1097/01.AOG.0000285998.75450.86. [13] M. H. Jagasia et al., «National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report», Biol. Blood Marrow Transplant., vol. 21, n. 3, pagg. 389-401.e1, mar. 2015, doi: 10.1016/j.bbmt.2014.12.001. [14] S. L. Corson, K. Sullivan, F. Batzer, C. August, R. Storb, e E. D. Thomas, «Gynecologic manifestations of chronic graft-versushost disease», Obstet. Gynecol., vol. 60, n. 4, pagg. 488–492, ott. 1982. [15] B. Frey Tirri et al., «Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD», Bone Marrow Transplant., vol. 50, n. 1, pagg. 3–9, gen. 2015, doi: 10.1038/ bmt.2014.242. [16] D. Shanis, M. Merideth, T. K. Pulanic, B. N. Savani, M. Battiwalla, e P. Stratton, «Female Long-Term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation: Evaluation and Management», Semin. Hematol., vol. 49, n. 1, pagg. 83–93, gen. 2012, doi: 10.1053/j.seminhematol.2011.10.002. [17] E. Carreras, C. Dufour, M. Mohty, e N. Kröger, A c. di, The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Cham: Springer International Publishing, 2019. doi: 10.1007/978-3-030-02278-5. [18] T. Miles e N. Johnson, «Vaginal dilator therapy for women receiving pelvic radiotherapy», Cochrane Database Syst. Rev., set. 2014, doi: 10.1002/14651858.CD007291.pub3. [19] K. L. Syrjala, B. F. Kurland, J. R. Abrams, J. E. Sanders, e J. R. Heiman, «Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years», Blood, vol. 111, n. 3, pagg. 989–996, feb. 2008, doi: 10.1182/blood-2007-06-096594. [20] F. L. Wong et al., «Longitudinal trajectory of sexual functioning after hematopoietic cell transplantation: impact of chronic graft-versus-host disease and total body irradiation», Blood, vol. 122, n. 24, pagg. 3973–3981, dic. 2013, doi: 10.1182/blood-2013-05-499806. [21] Z. Li et al., «Sexual health in hematopoietic stem cell transplant recipients: Sexual Health After Transplantation», Cancer,
RkJQdWJsaXNoZXIy ODUzNzk5